Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Sverdlovsk Regional Clinical Hospital No.1
Modality
other_biological
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Interstitial Cystitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hyaluronate (this asset) | Sverdlovsk Regional Clinical Hospital No.1 | P1 | CC · 43 |
| Continuous Microgestin 1/20 | Endeavor Health | P4 | BB |
| Cyclic Microgestin 1/20 | Endeavor Health | P4 | BB |
| Doxycycline | Insel Gruppe AG, University Hospital Bern | P4 | B |
| Gralise | Shirley Ryan AbilityLab | P4 | B |
| Amitriptyline | Jocelyn Fitzgerald | P3 | B |
| Gabapentin | Jocelyn Fitzgerald | P3 | B |
| Methenamine | Jocelyn Fitzgerald | P3 | B |
| Noramitriptyline | Duke University | P2 | B |
+16 more in the Interstitial Cystitis cohort
Other indications for Hyaluronate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Knee | — | P4 | BB · 68 |
| Chronic Pain Syndrome | — | P4 | BB · 66 |
| Breast Neoplasm | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Hyaluronate in Interstitial Cystitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hyaluronate-interstitial-cystitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →